Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Bundred, N, Porta, N, Brunt, AM et al. (20 more authors) (2022) Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research. ISSN 1078-0432

Abstract

Metadata

Authors/Creators:
  • Bundred, N
  • Porta, N
  • Brunt, AM
  • Cramer, A
  • Hanby, A ORCID logo https://orcid.org/0000-0001-7966-1570
  • Shaaban, AM
  • Rakha, EA
  • Armstrong, A
  • Cutress, RI
  • Dodwell, D
  • Emson, MA
  • Evans, A
  • Hartup, SM
  • Horgan, K
  • Miller, SE
  • McIntosh, SA
  • Morden, JP
  • Naik, J
  • Narayanan, S
  • Ooi, J
  • Skene, AI
  • Cameron, DA
  • Bliss, JM
Copyright, Publisher and Additional Information: © 2022 The Authors; Published by the American Association for Cancer Research. This open access article is distributed under the Creative Commons Attribution License 4.0 International (CC BY).
Dates:
  • Accepted: 20 January 2022
  • Published (online): 14 February 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Feb 2022 15:15
Last Modified: 16 Feb 2022 15:15
Status: Published online
Publisher: American Association for Cancer Research (AACR)
Identification Number: https://doi.org/10.1158/1078-0432.ccr-21-3177

Download

Share / Export

Statistics